Pharmacokinetics of the antiviral agent β-D-2′-deoxy-2′- fluoro-2′-C-methylcytidine in rhesus monkeys

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 2877-2882

  Asif, Ghazia ^a,c   Hurwitz, Selwyn J ^a,c   Shi, Junxing ^c,d   Hernandez Santiago, Brenda I ^a,c   Schinazi, Raymond F ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d RFS Pharma LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXY 2' FLUORO 2' C METHYLURIDINE; ANTIVIRUS AGENT; BETA DEXTRO 2' DEOXY 2' FLUORO 2' C METHYLCYTIDINE; BETA DEXTRO 2' DEOXY 2' FLUORO 2' METHYL N 4 PENTYLCARBONYLCYTIDINE; CYTIDINE DERIVATIVE; PSI 6130; PSI 6206; PSI 6419; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DEAMINATION; DRUG BIOAVAILABILITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STABILITY; DRUG STRUCTURE; DRUG URINE LEVEL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SINGLE DRUG DOSE; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CEREBROSPINAL FLUID; DEOXYCYTIDINE; ENZYME INHIBITORS; FEMALE; HUMANS; MACACA MULATTA; PRODRUGS; URINE;

EID: 34547632564     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00193-07     Document Type: Article

References (23)

1. Boudinot, F. D., R. F. Schinazi, J. M. Gallo, H. M. McClure, K. J. Doshi, P. C. Kambhampathi, and C. K. Chu. 1990. 3′-Azido-2′, 3′-dideoxyuridine (AzddU): comparative pharmacokinetics with 3′-azido-3′-deoxythymidine (AZT) in monkeys. AIDS Res. Hum. Retrovir. 6:219-228.
2. Cacoub, P., D. Saadoun, N. Limal, J. M. Leger, and T. Maisonobe. 2005. Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. AIDS 3:S128-S134.
3. Cappellari, A., L. Origgi, M. F. Spina, K. G. Yiannopoulou, G. Meola, M. Vanoli, A. Ciammola, F. Gregorini, R. Scorza, and N. Bresolin. 2006. Central nervous system involvement in HCV-related mixed cryoglobulinemia. Electromyogr. Clin. Neurophysiol. 46:149-158.
4. Carroll, S. S., J. E. Tomassini, M. Bosserman, K. Getty, M. W. Stahlhut, A. B. Eldrup, B. Bhat, D. Hall, A. L. Simcoe, R. LaFemina, C. A. Rutkowski, B. Wolanski, Z. Yang, G. Migliaccio, R. De Francesco, L. C. Kuo, M. MacCoss, and D. B. Olsen. 2003. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278:11979-11984.
5. Casato, M., D. Saadoun, A. Marchetti, N. Limal, C. Picq, P. Pantano, D. Galanaud, R. Cianci, P. Duhaut, J. C. Piette, M. Fiorilli, and P. Cacoub. 2005. Central nervous system involvement in hepatitis C virus cryoglobulinemia vasculitis: a multicenter case-control study using magnetic resonance imaging and neuropsychological tests. J. Rheumatol. 32:484-488.
6. Chen, H., F. D. Boudinot, C. K. Chu, H. M. McClure, and R. F. Schinazi. 1999. Pharmacokinetics of (-)-β-D-dioxolane guanine and prodrug (-)-β-D-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res. Hum. Retrovir. 15:1625-1630.
7. Chen, H., S. B. Pai, S. J. Hurwitz, C. K. Chu, Y. Glazkova, H. M. McClure, M. Feitelson, and R. F. Schinazi. 2003. Antiviral activity and pharmacokinetics of 1-(2,3-dideoxy-2-fluoro-β-L-glyceropent-2- enofuranosyl)cytosine. Antimicrob. Agents Chemother. 47:1922-1928.
8. Clark, J. L., L. Hollecker, J. C. Mason, L. J. Stuyver, P. M. Tharnish, S. Lostia, T. R. McBrayer, R. F. Schinazi, K. A. Watanabe, M. J. Otto, P. A. Furman, W. J. Stec, S. E. Patterson, and K. W. Pankiewicz. 2005. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro- 2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48:5504-5508.
9. Clifford, D. B., Y. Yang, and S. Evans. 2005. Neurologic consequences of hepatitis C and human immunodeficiency virus coinfection. J. Neurovirol. 11:67-71.
10. De Clercq, E., and H. J. Field. 2006. Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy. Br. J. Pharmacol. 147:1-11.
11. Eldrup, A. B., M. Prhavc, J. Brooks, B. Bhat, T. P. Prakash, Q. Song, S. Bera, N. Bhat, P. Dande, P. D. Cook, C. F. Bennett, S. S. Carroll, R. G. Ball, M. Bosserman, C. Burlein, L. F. Colwell, J. F. Fay, O. A. Flores, K. Getty, R. L. LaFemina, J. Leone, M. MacCoss, D. R. McMasters, J. E. Tomassini, D. Von Langen, B. Wolanski, and D. B. Olsen. 2004. Structure-activity relationship of heterobase-modified 2′-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem. 47:5284-5297.
12. Gabrielsson, J., and D. Weiner (ed.). 2000. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications, 3rd ed. Apotekarsocieteten, Stockholm, Sweden.
13. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed., Marcel Dekker, Inc., New York, NY.
14. Hurwitz, S. J., M. J. Otto, and R. F. Schinazi. 2005. Comparative pharmacokinetics of Racivir, (±)-β-2′,3′-dideoxy-5- fluoro-3′-thiacytidine, in rats, rabbits, dogs, monkeys and HIV-infected humans. Antivir. Chem. Chemother. 16:117-127.
15. Lindsay, K. L., C. Trepo, T. Heintges, M. L. Shiftman, S. C. Gordon, J. C. Hoefs, E. R. Schiff, Z. D. Goodman, M. Laughlin, R. Yao, J. K. Albrecht, and the Hepatitis Interventional Therapy Group. 2001. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395-403.
16. Ludmerer S. W., D. J. Graham, E. Boots, E. M. Murray, A. Simcoe, E. J. Markel, J. A. Grobler, O. A. Flores, D. B. Olsen, D. J. Hazuda, and R. L. LaFemina. 2005. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49:2059-2069.
17. McHutchison, J. G., S. C. Gordon, E. R. Schiff, M. L. Shiffman, W. M. Lee, V. K. Rustgi, Z. D. Goodman, M. H. Ling, S. Cort, and J. K. Albrecht. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
18. Murakami, E., H. Bao, M. Ramesh, T. R. McBrayer, T. Whitaker, H. M. Micolochick Steuer, R. F. Schinazi, L. J. Stuyver, A. Obikhod, M. J. Otto, and P. A. Furman. 2007. Mechanism of activation of β-D-2′- deoxy-2′-fluoro-2′-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51:503-509.
19. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
20. Schinazi, R. F., F. D. Boudinot, S. Ibrahim, C. Manning, H. M. McClure, and D. C. Liotta. 1992. Pharmacokinetics and metabolism of racemic 2′,3′-dideoxy-5-fluoro-3′-thiacytidine in rhesus monkeys. Antimicrob. Agents Chemother. 36:2432-2438.
21. Schinazi, R. F., F. D. Boudinot, K. J. Doshi, and H. M. McClure. 1990. Pharmacokinetics of 3′-fluoro-3‰-deoxythymidine and 3‰-deoxy-2‰,3‰-didehydrothymidine in rhesus monkeys. Antimicrob. Agents Chemother. 34:1214-1219.
22. Shah, V. P., K. K. Midha, J. W. A. Findlay, H. M. Hill, J. D. Hulse, I. J. McGilveray, G. McKay, K. J. Miller, R. N. Patnaik, M. L. Powell, A. Tonelli, C. T. Viswanathan, and A. Yacobi. 2000. Bioanalytical method validation - a revisit with a decade of progress. Pharm. Res. 17:1551-1557.
23. Wright, J. D., T. Ma, C. K. Chu, and F. D. Boudinot. 1996. Discontinuous oral absorption pharmacokinetic model and bioavailability of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl)uracil (L-FMAU) in rats. Biopharm. Drug Dispos. 17:197-207.